Aggressive Diffuse Large B-cell Lymphoma research hub

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

This study looks at a new combination of two medicines, Loncastuximab Tesirine and Epcoritamab, for people in the UK with aggressive B-cell lymphoma that has come back or hasn't responded to previous treatments. It's for adults aged 18 and over.